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Background: Previous studies demonstrated a significant correlation between pre-procedural glycemic levels and post-procedural creatinine 
increase in patients undergoing percutaneous coronary intervention (PCI). However, of late, the degree of glucose fluctuations, rather than the 
absolute value of glycemia, seems to better estimate patients’ metabolic status. Thus, the aim of this study is to evaluate the correlation between 
glycemic variability (measured by a subcutaneous continuous glucose monitoring system, iPro™, during and after PCI) and creatinine increase after 
contrast administration.
Methods: The population consisted of 22 patients with diabetes mellitus type 2 or impaired glucose tolerance, who underwent PCI at our 
institution. At hospitalization, the iPro™ was positioned onto enrolled patients in order to measure glycemic fluctuations in the periprocedural (up to 
24 hours after PCI) and postprocedural (from 24 hours to 6 days) period. Glycemic variability was expressed by the glycemic Coefficient of Variability 
(CV - ratio between standard deviation and average of all measured glycemic values) and the Mean Amplitude Glycemic Excursions (MAGE, the 
arithmetical mean of the amplitude of all glycemic excursions measured between peaks and nadirs; in particular, MAGE+ considering only nadir-to-
peak excursions and MAGE- peak-to-nadir fluctuations). Blood samples were collected before and at 6 and 24 hours after PCI to measure creatinine 
levels.
Results: A post-procedural increase in creatinine levels was observed in 12 patients (55%). Those patients showed higher glycemic variability 
measured as CV (30% vs 24% in patients without renal function deterioration, p=0.06). The MAGE were 69 mg/dL and 57 mg/dL in patients with 
and without creatinine increase (p=0.27), with MAGE+ 76 mg/dL vs 57 mg/dL (p=0,12) and MAGE- 59 mg/dL vs 58 mg/dL (p=0,90), respectively.
Conclusions: This study evaluates, for the first time, the usefulness of continuous glucose monitoring through iPro™ in patients with impaired 
glucose metabolism undergoing PCI, demonstrating the correlation between peri- and post-procedural glycemic variability and creatinine increase 
after contrast injection.
